News

Precision Medicine - Biomarkers & Diagnostics test post

ACOBIOM presents the clinical benefit of GemciTesT at ASCO 2021

ACOBIOM presents the clinical benefit of GemciTest® at ASCO 2021

The abstract presented at the 2021 ASCO Annual Conference is a study synthesis of the clinical performance of the CE-IVD molecular test to assess the gemcitabine response in advanced pancreatic cancer.

Acobiom bénéficie d'un financement européen pour le Gemcitest

Acobiom’s Gemcitest receives a European financial support

Within the framework of the SME Instrument-Phase 1 call for projects, Europe provided a financial support to ACOBIOM in order to evaluate the costs of the current management of pancreatic cancer in France. This study will confirm the sale forecasts of the GemciTest in France and in Europe.

Financing of ACOBIOM's GemciTest on the WEDOGOOD crowdfunding platform

Crowdfunding for ACOBIOM in 2020

Despite a difficult context in 2020 due to the COVID pandemic, Acobiom managed to raise more than 100,000 euros on the social impact crowdfunding platform WeDoGood.

Sequence of nucleotides

The RNA at the heart of Life

Produced by DNA, RNA is among the least known constituents of the life sciences and the least cited in publications, communications or media. RNA is delicate to use by technicians and always enigmatic for most scientists.

GemciTest - In vitro diagnostic medical device for the prediction of patient response in the treatment of the pancreas with gemcitabine

Publication in the Cancers journal on the benefits of GemciTest®

A scientific publication in Cancers, a peer reviewed scientific journal, presents the capabilities of Acobiom’s GemciTest® to identify the pancreatic cancer patients who are most likely to benefit from gemcitabine-based treatment as the first approach.

Pink Ribbon - The Jerome Lejeune Institute and ACOBIOM identified recently new prognostic factors in breast cancer

The Jerome Lejeune Institute and ACOBIOM identified recently new prognostic factors in breast cancer

In a recent study, ACOBIOM, in partnering with the Jerome Lejeune Institute, characterized molecular mechanisms that could help to better understand the decreased incidence of Breast Cancer in women with Down Syndrome (Trisomy 21).

AG2R LA MONDIALE supports the GemciTest®

AG2R LA MONDIALE supports the improvement of medical management of pancreatic cancer with GemciTest®

Acobiom announces the CE marking of GemciTest®

GemciTest®, an in-vitro diagnostic that predicts the patient’s response to one of the therapies used to treat pancreatic cancer, benefits now from CE marking, which means it complies with current European regulations in force. Acobiom develops innovative blood diagnostics in the field of precision medicine. These tests, based on liquid biopsies (blood), aim to give…
Read more

World Pancreatic Cancer Day 2019 Banner

World Pancreatic Cancer Day 2019

On next November 21, 2019, the World Pancreatic Cancer Day 2019 will be organized. Key information about pancreatic cancer Pancreatic cancer is one of the world’s deadliest cancers. This cancer develops when cells of the organs grow out of control, developing a tumor. The pancreas is a gland located deep in the abdomen, between the…
Read more

How Artificial Intelligence can help to the devlopment of diagnostics dedicated to Precision Medicine

How Artificial Intelligence can help to the development of diagnostics dedicated to Precision Medicine

Generating sequencing data from patient blood samples became easy to perform in clinical trials. But, analyzing the huge amount of genomic or transcriptomic data and extracting the key biomarkers associated with a clinical response to a specific therapy needs a tremendous combination of a scientific expertise, a biomolecular know-how, and a panel of bioinformatics and…
Read more